Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Retatrutide is investigational and not approved for human use
William Kennedy shares, "I would consider prescribing BPC-157 for patients with chronic soft tissue injuries, tendon or ligament damage, or delayed healing when conventional therapies have not produced the desired results
Current pricing (subject to change) typically starts around $124-$169 for the first month depending on protocol specifics, with ongoing monthly costs varying based on dosage, frequency, and program duration
CJC-1295 Without DAC (Modified GRF 1-29) and Ipamorelin are not licensed medicines or drugs and have not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals
US$ 23.45
US$ 25.12
US$ 28.47
US$ 25.60
